Conference summaries


T2D TREATMENT

The LIBERATES Trial - improving gLucose control in patIents with diaBEtes following myocardial infArction: the role of a novEl glycaemic monitoring Strategy

Presented by: Robert Storey, MMD; Deborah Stocken, MD; Ramzi Ajjan, MD

DIABETES & PREGNANCY

20 years HAPO Study: What have we learned so far?

Presented by: Patrick M. Catalano, MD
Expert commentary by Elizabeth O. Buschur, MD

TREATMENT

Multifactorial treatment of diabetes: 10-year follow-up of the ADDITION-EUROPE study

Presented by: Simon Griffin, MD

DIABETES & HF

Empagliflozin for the treatment of chronic heart failure and a reduced ejection fraction in patients with and without diabetes: new results of the EMPEROR-Reduced trial

Presented by: Javed Butler, MD; Milton Packer, MD; Stefen D.Anker, MD; Gerasimos Filippatos, MD; Faiez Zannad, MD
Expert commentary by Prof. Francesco Giorgino

T1D & CVD

Incident cardiovascular disease by clustering of favourable risk factors in type 1 diabetes – The EURODIAB Prospective Complications study

Presented by: Soraya Soulimane, MD

DIABETES & PREGNANCY

Risk of major congenital malformations, perinatal or neonatal death with insulin detemir vs other basal insulins in pregnant women with pre-existing diabetes: the EVOLVE study

Presented by: Elisabeth Mathiesen, MD

T1D & COMPLICATIONS

Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: substudy of the RESCUE-trial

Presented by: Anass El Malahi, MD

T2D & CVD

Cardiovascular outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real life

Presented by: Gian Paolo Fadini, MD

T2D & CVD

Empagliflozin reduces myocardial glucose uptake in persons with type 2 diabetes: a randomised double-blind, placebo-controlled crossover study

Presented by: Katrine M. Lauritsen, MD

T2D TREATMENT

Once-weekly exenatide effects on eGFR slope and UACR as a function of baseline UACR: an EXSCEL trial post-hoc analysis

Presented by: Annemarie B. Van der Aart, PharmD

T2D TREATMENT

Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes

Presented by: Valentina Pirro, MDn

T2D & CVD

Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND

Presented by: Hertzel C. Gerstein, MD

T2D & CVD

CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries

Presented by: Ofri Mosenzon, MD, PhD

T1D & GLUCOSE CONTROL

Automated insulin delivery in free-life shows better glucose control when used 24/7 vs evening and night in pre-pubertal children with type 1 diabetes: the Free-life Kid AP Study

Presented by: Eric M. Renard, MD, PhD

T2D COMPLICATIONS

Effects of intensive risk factor management on cardiovascular autonomic neuropathy in type 2 diabetes: findings from the ACCORD clinical trial

Presented by: Rodica Pop-Busui, MD, PhD